ERBB2 and neoplasm: In order to exemplify ClinOmicsTrailbc‘s thorough assessment of these factors, we consider the tumor sample of a 41-year-old woman with a stage II, hormone receptor-positive, HER2-negative breast tumor (TCGA-BH-A0DT).